HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia.

Abstract
A patient is reported who developed essential thrombocythemia after successful treatment for hairy cell leukemia. He was initially treated with interferon alfa and subsequently relapsed within one year of treatment. His diagnosis was reconfirmed and then treated with Pentostatin. Six years after treatment he had a progressive increase in the platelet count and was diagnosed as essential thrombocythemia. Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa. These malignancies may represent either a new clonal disorder or a complication of drug treatment. This is the first report of a chronic myeloproliferative disorder following successful treatment of hairy cell leukemia.
AuthorsS M Lichtman, T Wasil, M Ahmad, J Brody
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 28 Issue 3-4 Pg. 423-7 (Jan 1998) ISSN: 1042-8194 [Print] United States
PMID9517515 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
  • Interferon-alpha
  • Pentostatin
Topics
  • Aged
  • Antibiotics, Antineoplastic (therapeutic use)
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Biopsy
  • Bone Marrow Cells (pathology)
  • Humans
  • Interferon-alpha (adverse effects, therapeutic use)
  • Leukemia, Hairy Cell (complications, drug therapy, pathology)
  • Male
  • Pentostatin (therapeutic use)
  • Recurrence
  • Thrombocytosis (chemically induced, etiology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: